Cyclosporine-Induced Autoimmunity and Immune Hyperreactivity

References

• Borel J F. Pharmacology of cyclosporine (sandimmune). 4. Pharmacological properties in vivo. Pharmacological Reviews 1989; 41: 259–370
   Web of Science ®Google Scholar
• Dipadova F E. Pharmacology of cyclosporine (sandimmune). 5. Pharmacological effects on immune function ‐ In vitro studies. Pharmacological Reviews 1989; 41: 373–405
   Google Scholar
• Ryffel B. Pharmacology of cyclosporine. 6. Cellular activation ‐ Regulation of intracellular events by cyclosporine. Pharmacological Reviews 1989; 41: 407–422
   Web of Science ®Google Scholar
• Feutren G. Cyclosporin‐A ‐ Recent developments in the mechanism of action and clinical application. Current Opinion in Immunology. 1989; 2: 239–245
   PubMedGoogle Scholar
• Kahan B D. Drug therapy ‐ cyclosporine. New Engl J Med. 1989; 321: 1725–1738
   PubMed Web of Science ®Google Scholar
• Kay J E. Inhibitory effects of cyclosporin A on lymphocyte activation. Cyclosporin. Mode of Action and Clinical Applications, A W Thomson. Kluwer Academic Publishers, Dordrecht 1989; 1–23
   Google Scholar
• Hess A D. Effect of cyclosporin A on the immune response: pivotal role of the inierleukin‐2/interleukin‐2 receptor autocrine pathway. Cyclosporin. Mode of Action und Clinical Applications, A W Thompson. Kluwer Academic Publishers, Dordrecht 1989; 24–33
   Google Scholar
• Thomson A W, Duncan J I. The influence of cyclosporin A on T cell activation, cytokine gene expression and cell‐mediated immunity. Cyclosporin. Mode of Action und Clinical Applications, A W Thompson. Kluwer Academic Publishers, Dordrecht 1989; 30–81
   Google Scholar
• Alexander D R, Cantrell D A. Kinases and phosphatases in T‐cell activation. Immunol Today. 1989; 10: 200–205
   PubMedGoogle Scholar
• Redelman D. Cyclosporin A does not inhibit the PHA‐stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E‐rosette receptor (CD2) expression and appearance of interleukin‐2 receptors (CD25). Cytometry. 1988; 9: 156–163
   PubMedGoogle Scholar
• Metcalfe S. Cyclosporin does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation. 1984; 38: 161–164
   PubMed Web of Science ®Google Scholar
• Isakov N, Scholz W, Altman A. Effect of cyclosporine A on early stages of T cell activation. Transplant Proc. 1987; 14: 1186–1188
   Google Scholar
• Elliott J F, Lin Y, Mizel S B, Bleackley R C, Harnish D G, Paetkau V. Induction of interleukin‐2 messenger RNA inhibited by cyclosporin. A. Science. 1984; 226: 1439–1441
   PubMed Web of Science ®Google Scholar
• Colombani P M, Robb A, Hess A D. Cyclosporine A binding to calmodulin: a possible site of action on T lymphocytes. Science 1985; 228: 337–339
   PubMed Web of Science ®Google Scholar
• Fischer G, Wittmann‐Liebold B, Lang K, Kiefhaber T, Schmid F X. Cyclophilin and peptidyl‐prolyl cis‐trans isomerase are probably identical proteins. Nature 1989; 337: 476–478
   PubMed Web of Science ®Google Scholar
• Citterio F, Kahan B D. The inhibitory effect of cyclosporine on the nuclear proliferative response to a variety of T cell activators. Transplantation. 1989; 47: 334–338
   PubMedGoogle Scholar
• Emmel E A, Verweij C L, Durand D B, Higgins K M, Lacy E, Crabtree G R. Cyclosporin‐A specifically inhibits function of nuclear proteins involved in T‐cell activation. Science 1989; 246: 1617–1620
   PubMed Web of Science ®Google Scholar
• Foxwell B M J, Simon J, Herrero J J, Taylor D, Woerly G, Cantrell D, et al. Anti‐CD3 antibody‐induced expression of both P55 and P75 chains of the high affinity interleukin‐2 receptor on human lymphocytes‐T is inhibited by cyclosporin‐A. Immunology. 1990; 69: 104–109
   PubMedGoogle Scholar
• Granelli‐Piperno A, Keane M, Steinman R M. Evidence that cyclosporine inhibits cell‐mediated immunity primarily at the level of the T lymphocyte rather than the accessory cell. Transplantation. 1988; 46: 53S–60S
   Web of Science ®Google Scholar
• Motta I, Truffa‐Bachi P. Influence of cyclosporin A on humoral immunity and on B lymphocyte activation. Cyclosporin. Mode of Action and Clinical Applications, A W Thomson. Kluwer Academic Publishers, Dordrecht 1989; 34–69
   Google Scholar
• Esa A H, Converse P J, Hess A D. Cyclosporine inhibits soluble antigen and alloantigen presentation by human monocytes in vitro. Int J Immunopharmacol. 1987; 9: 893–902
   PubMedGoogle Scholar
• Little R G, Ebertowski L A, David C S. Inhibition of alloantigen presentation by cyclosporine. Transplantation. 1990; 49: 937–944
   PubMedGoogle Scholar
• Halloran P F, Urmson J, Farkas S, Phillips R A, Fulop G, Cockfield S, et al. Effects of cyclosporine on systemic MHC expression. Evidence that non‐T cells produce interferon‐gamma in vivo and are inhibitable by cyclosporine. Transplantation. 1988; 46: 68s–72s
   PubMed Web of Science ®Google Scholar
• Granelli‐Piperno A. In situ hybridization for interleukin‐2 and interleukin‐2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med. 1988; 168: 1649–1658
   PubMedGoogle Scholar
• Pereira G, Miller J F, Shevach E M. Mechanism of action of cyclosporine A in vivo I. I. T cell priming in vivo to alloantigen can be mediated by an IL‐2‐independent cyclosporine A‐resist‐ant pathway. J Immunol. 1990; 144: 2109–2116
   PubMedGoogle Scholar
• Chisholm P M, Bevan D J. T cell activation in the presence of cyclosporine in three in vivo allograft models. Transplantation. 1988; 46: 80s–85s
   Google Scholar
• Chisholm P M, Drayson M T, Cox J H, Ford W L. The effects of cyclosporin on lymphocyte activation in a systemic graft‐vs‐host reaction. Eur J Immunol. 1985; 15: 1054–1059
   PubMedGoogle Scholar
• June C H, Ledbetter J A, Linsley P S, Thompson C B. Role of the CD28 receptor in T‐cell activation. Immunol Today. 1990; 11: 211–216
   PubMedGoogle Scholar
• Aten J, Bosman C B, De Heer E, Heodemaeker P J, Weening J J. Cyclosporin A induces long‐term unresponsiveness in mercuric chloride‐induced autoimmune glomerulonephritis. Clin Exp Immunol. 1988; 73: 307–311
   PubMedGoogle Scholar
• Heeg K, Gillis S, Wagner H. IL‐4 bypasses the immune suppressor effect of cyclosporin A during the in vitro induction of murine cytotoxic T lymphocytes. J Immunol. 1988; 141: 2330–2334
   PubMedGoogle Scholar
• Noble R L, Steinmuller D. Blocking of interleukin‐2 production, but not the tissue destruction induced by cytotoxic T cells, by cyclosporine. Transplantation. 1989; 47: 322–326
   PubMed Web of Science ®Google Scholar
• Schiltknecht E, Ada G L. The generation of effector T cells in influenza‐A infected, cyclosporin A‐treated mice. Cell Immunol. 1985; 95: 340–350
   PubMedGoogle Scholar
• White D J G, Lim S M L. The induction of tolerance by cyclosporine. Transplantation. 1988; 46: 1185–1215
   Google Scholar
• Thomson A W, Aldridge R D. Absence of dependence on cyclophosphamide‐sensitive suppressor cells in suppression of cell‐mediated immunity in CsA in the guinea pig. Transplantation. 1984; 38: 76–77
   PubMedGoogle Scholar
• Aldridge R D, Thompson A W. Paradoxical augmentation of tuberculin‐like hypersensitivity, but not Jones‐Mote or contact hypersensitivity. in cyclosporin A treated guinea pigs. Int Arch Allergy Appl Immunol. 1986; 79: 225–230
   PubMedGoogle Scholar
• Webster L M, Thomson A W. Cyclosporin A prevents suppression of delayed‐type hypersensitivity in mice immunized with high dose sheep erythrocytes. Immunology. 1987; 60: 409–414
   PubMedGoogle Scholar
• Webster L M, Thomson A W. Augmentation of delayed‐type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol. 1988; 71: 149–154
   PubMedGoogle Scholar
• Aldridge R D, Thomson A W. Factors influencing the enhancement of DTH to ovalbumin by CsA in the guinea pig; possible role of suppressor cells. Int Arch Allergy Appl Immunol. 1986; 81: 17–23
   PubMedGoogle Scholar
• Mosmann T R, Coffman R L. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol. 1989; 7: 145–173
   PubMed Web of Science ®Google Scholar
• Fernandez‐Botran R, Sanders V M, Mosmann T R, Uhr S W, Vitetta E S. Lymphokine‐mediated regulation of the proliferative response of clones of Th1 and Th2 cells. J Exp Med. 1988; 168: 543–558
   PubMed Web of Science ®Google Scholar
• Gajewski T F, Fitch F W. Anti‐proliferative effect of IFN‐gamma in immune regulation. I. IFN‐gamma inhibits the proliferation of TH2 but not TH1 murine THL clones. J Immunol. 1988; 140: 4245–4252
   PubMed Web of Science ®Google Scholar
• Fiorentino D F, Bond M W, Mosmann T R. Two types of mouse T helper cell I. V. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170: 2081–2095
   PubMed Web of Science ®Google Scholar
• Lohoff M, Marsig E, Rollinghoff M. Murine IL‐4 antagonizes the protective effects of IFN on virus‐mediated lysis of murine L929 fibroblast cells. J Immunol. 1990; 144: 960–963
   PubMedGoogle Scholar
• Bretscher P A. Significance and mechanisms of cellular regulation of the immune response. Fed Proc. 1981; 40: 1473–1478
   PubMedGoogle Scholar
• Behforouz N C, Weryer C D, Mathison B A. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B‐5–49 enhances resistance to Leishmania Major. J Immunol. 1986; 136: 3067–3075
   PubMedGoogle Scholar
• Locksley R M, Heinzel F P, Sadick M D, Holaday B J, Bardner K D, Jr. Murine cutaneous Leishmaniasis: Susceptibility correlates with differential expansion of helper T‐cell subsets. Ann Inst Past/Immunol. 1987; 138: 744–749
   PubMedGoogle Scholar
• Chen S ‐S, Stanescu G, Magalski A E, Qian Y ‐Y. Cyclosporin A is an adjuvant in murine IgE antibody responses. J Immunol. 1989; 142: 4225–4232
   PubMedGoogle Scholar
• Gajewski T F, Schell S R, Fitch F W. Evidence implicating utilization of different T cell receptor associated signalling pathways by Thl and Th2 clones. J Immunol;. 1990; 144: 4110–4120
   PubMed Web of Science ®Google Scholar
• Ryffel B, Feurer C, Heuberger B, Borel J F. Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment. Immunobiology. 1982; 163: 470–473
   PubMedGoogle Scholar
• Gratwohl A, Speck B. Bone marrow transplantation with cyclosporin. Prog Allergy 1986; 38: 404–431
   PubMedGoogle Scholar
• Sliman G A, Beschorner W E, Baughman K L, Hutchins G M, Borkon M A, Baumgartner W A. Graft‐vs‐host disease in a heart allograft recipient: A possible autoimmune phenomenon. Transplantation. 1988; 45: 253–256
   PubMedGoogle Scholar
• Herman J G, Beschorner W E, Baughman K L, Boitnott J K, Vogelsang G B, Baumgartner W A. Pseudo‐graft‐vs‐host disease in heart and heart‐lung recipients. Transplantation. 1988; 46: 93–98
   PubMedGoogle Scholar
• Myburgh J A. Total lymphoid irradiation in transplantation. Transplant Proc. 1988; 20: 118–121
   PubMedGoogle Scholar
• Bachavaroff R J, Alsiyarma W, Sato T, Rapaport F T, Calane R Y. Paradoxical effects of cyclosporin A in renal allotransplantation. Transplant Proc. 1981; 13: 414
   Google Scholar
• Von Graffenried B. Cyclosporine A (sandimmune) in autoimmune disorders. Cyclosporin. Mode of Action and Clinical Applications, A W Thompson. Kluwer Academic Publishers, Dordrecht 1989; 213–251
   Google Scholar
• Kaibara N, Hotokebuchi T, Takagishi K, Katsuki I. Paradoxical effects of cyclosporin A on collagen arthritis in rats. J Exp Med. 1983; 158: 2007–2015
   PubMed Web of Science ®Google Scholar
• Cohen I R. Regulation of autoimmune disease: physiological and therapeutic. Immunol Rev. 1986; 94: 5–21
   PubMed Web of Science ®Google Scholar
• Polman C H, Matthaei I, De Groot C J A, Koetsier J C, Sminia T, Dijkstra C D. Low‐dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol. 1988; 17: 209–216
   PubMedGoogle Scholar
• Feurer C, Chow L H, Borel J F. Preventative and therapeutic effects of cyclosporine and valine2‐dihydro‐cyclosporine in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Immunology. 1988; 63: 219–223
   PubMedGoogle Scholar
• Chow L H, Feurer C, Borel J F. Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat: studies on immune regulation. J Neuroimmunol. 1988; 19: 329–339
   PubMed Web of Science ®Google Scholar
• Reiber H, Suckling A J. Cyclosporin‐A treatment of experimental allergic encephalomyelitis: changes in immunological regulation and blood‐CSF barrier function. J. Neuroimmunol. 1986; 12: 121–130
   PubMedGoogle Scholar
• Reiber H, Kitze B, Link M, Wagner R. Cellular immune reactions and blood cerebrospinal fluid barrier dysfunction in guinea pigs. Neurochem Res. 1988; 13: 463–466
   PubMedGoogle Scholar
• Fredane L M, Hashim G A, McCabe R E. The effect of cyclosporine on lymphocyte subsets in experimental allergic encephalomyelitis: functional loss of disease‐suppressing cells in vivo. Transplant Proc. 1983; 15: 2909–2913
   Google Scholar
• Ellerman K E, Powers J M, Brostoff S W. A suppressor T‐lymphocyte cell line for autoimmune encephalomyelitis. Nature 1989; 331: 265–267
   Google Scholar
• Wick G, Muller P U, Schwarz S. Effect of cyclosporin A on spontaneous autoimmune thyroiditis of obese strain (OS) chickens. Eur J Immunol. 1982; 12: 877–881
   PubMedGoogle Scholar
• Howlett T A, Lawton N F, Fells P, Besser G M. Deterioration of severe Grave's ophthalmopathy during cyclosporine treatment. Lancet. 1984; ii: 1101
   Google Scholar
• Kolb H, Oschilewski M, Schwab E, Oschilewski U, Kiesel U. Effect of cyclosporin A on low‐dose streptozotocin diabetes in mice. Diabetes Res. 1985; 2: 191–193
   PubMedGoogle Scholar
• Sestier C, Odent‐Pogu S, Bonneville M, Maurel C, Lang F, Sai P. Cyclosporin enhances diabetes induced by low‐dose streptozotocin treatment in mice. Immunol Lett. 1985; 10: 57–60
   PubMedGoogle Scholar
• Iwakiri R, Nagafuchi S, Kounoue E, Nakano S, Koga T, Nakayama M, Nakamura M, Niho Y. Cyclosporin A enhances streptozotocin‐induced diabetes in CD‐1 mice. Experientia (Basel). 1987; 43: 324–327
   PubMedGoogle Scholar
• Jansson L, Sandler S. The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes induced by multiple low doses of streptozotocin in the mouse. Virchows Arch (A) Path Anat Histopathol. 1988; 41: 225–230
   Google Scholar
• Fite K V, Pardue S, Benston L, Hayden D, Smyth J R. Effects of cyclosporine in spontaneous posterior uveitis. Curr. Eye Res. 1986; 5: 787–796
   PubMed Web of Science ®Google Scholar
• Pardue S L, Fite K V, Bengston L, Lamont S J, Boyle M L, Smyth J R. Enhanced integumental and ocular amelanosis following the termination of cyclosporine administration. J Invest Dermtol. 1987; 88: 758–761
   PubMed Web of Science ®Google Scholar
• Estrin M, Huber S. Coxsackievirus B3‐induced myocarditis. Autoimmunity is L3T4+T helper cell and IL‐2 independent in BALB/c mice. Am J Pathol. 1987; 127: 335–341
   PubMedGoogle Scholar
• Estrin M, Smith C, Huber S. Coxsackievirus B‐3 myocarditia. T‐cell autoimmunity to heart antigens is resistant to cyclospor‐in‐A treatment. Am J Pathol. 1986; 125: 244–251
   PubMedGoogle Scholar
• Huber S A, Lodge P A. Coxsackie B‐3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and BALB/c mice. Am J Pathol. 1986; 122: 284–291
   PubMedGoogle Scholar
• Fukuzawa M, Shearer G M. Effect of cyclosporin‐A on T‐cell immunity. I. Dose‐dependent suppression of different murine T‐helper cell pathways. Eur J Immunol. 1989; 19: 49–56
   PubMed Web of Science ®Google Scholar
• Hall B M, Pearce N W, Gurley K E, Dorsch S E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. J Exp Med. 1990; 171: 141–157
   PubMed Web of Science ®Google Scholar
• Glazier A, Tutschka P J, Farmer E R, Santos G W. Graft‐versus‐host disease in cyclosporin‐A treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med. 1983; 158: 1–8
   PubMed Web of Science ®Google Scholar
• Sorokin R, Kimura H, Schroder K, Wilson D H, Wilson D B. Cyclosporine‐induced autoimmunity: conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug‐treated rats. J Exp Med. 1986; 164: 1615–1616
   PubMed Web of Science ®Google Scholar
• Bos G M J, Majoor G D, Van Breda‐Vriesman P J C. Cyclosporin‐A induces a selective, reversible suppression of T‐helper lymphocyte regeneration after syngeneic bone marrow transplantation: association with syngeneic graft‐versus‐host disease in rats. Clin Exp Immunol. 1988; 74: 443–448
   PubMed Web of Science ®Google Scholar
• Parfrey N A, Prud'homme G J. Patterns of MHC antigenic modulation in cyclosporine‐induced autoimmunity. Implications for pathogenesis. Am J Pathol. 1990; 136: 479–486
   PubMedGoogle Scholar
• Beschorner W E, DiGennaro K A, Hess A D, Santos G W. Cyclosporine and the thymus: influence of irradiation and age on thymic immunopathology and recovery. Cell Immunol. 1987; 112: 350–363
   Google Scholar
• Cheney R T, Sprent J. Capacity of cyclosporine to induce auto‐graft‐versus‐host disease and impair intrathymic T cell differentiation. Transplant Proc. 1985; 17: 528–530
   Web of Science ®Google Scholar
• Chow L H, Mosbach‐Ozmen L, Ryffel B, Borel J F. Syngeneic graft‐versus‐host disease induced by cyclosporine‐A reappraisal. Transplantation. 1988; 46: 107s–112s
   Google Scholar
• Prud'homme G J, Sanders R, Parfrey N A, Ste‐Croix H. T cell maturation and clonal deletion in cyclosporine‐induced autoimmunity. J Autoimmunity.
   Google Scholar
• Bryson J S, Jennings C D, Caywood B E, Kaplan A M. Induction of a syngeneic graft‐versus‐host disease‐like syndrome in DBA/2 mice. Transplantation. 1989; 48: 1042–1047
   PubMed Web of Science ®Google Scholar
• Jones R J, Hess A D, Mann R B, Piantadosi S, Vogelsang G B, Farmer E R, et al. Induction of graft‐vs‐host disease after autologous bone marrow transplantation. Lancet. 1989; i: 754–757
   Google Scholar
• Dale B M, Atkinson K, Kotasek D, Biggs J C, Sage R E. Cyclosporine‐induced graft‐vs‐host disease in two patients receiving syngeneic bone marrow transplants. Transplant Proc. 1989; 21: 3816–3817
   PubMed Web of Science ®Google Scholar
• Hood A F, Vogelsang G B, Black L P, Farmer E R, Santos G W. Acute graft‐vs‐host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol. 1987; 123: 745–750
   PubMed Web of Science ®Google Scholar
• VanBekkum D W. Comments on syngeneic GVHD. Immunol Today. 1990; 11: 107
   PubMedGoogle Scholar
• Beschorner W E, Hess A D, Shinn C A, Santos G W. Transfer of cyclosporine‐associated syngeneic graft‐versus‐host disease by thymocytes. Transplantation. 1988; 45: 209–215
   PubMed Web of Science ®Google Scholar
• Fischer A C, Beschorner W E, Hess A D. Requirements for the induction and adoptive transfer of cyclosporine‐induced syngeneic graft‐vs‐host disease. J Exp Med. 1989; 169: 1031–1041
   PubMed Web of Science ®Google Scholar
• Hess A D, Horwitz L, Beschorner W E, Santos G W. Development of graft‐vs‐host disease‐like syndrome in cyclosporine‐treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent poly‐clonal anti‐Ia specificity, including autoreactivity. J Exp Med. 1985; 161: 718–730
   PubMed Web of Science ®Google Scholar
• Beschorner W E, Shinn Ca, Fischer A C, Santos G W, Hess A D. Cyclosporine‐induced pseudo‐graft‐versus‐host disease in the early post‐cyclosporine period. Transplantation. 1988; 46: 112s–117s
   Google Scholar
• Parfrey N A, Ste‐Croix H, Prud'homme G J. Evidence that non‐lymphoid tissue injury in acute graft‐vs‐host disease is limited to epithelial cells aberrantly expressing MHC antigens. Transplantation. 1989; 48: 655–460
   PubMedGoogle Scholar
• Gaspari A A, Katz S I. Induction and functional characterization of class II MHC (Ia) antigens on murine keratinocytes. J Immunol. 1988; 140: 2956–2962
   PubMedGoogle Scholar
• Prud'homme G J, Sohn U, Delovitch T L. The role of H‐2 and Ia antigens in graft‐vs‐host reactions. J Exp Med. 1979; 149: 137–149
   PubMedGoogle Scholar
• Hess A D, Fischer A C. Immune mechanisms in cyclosporine‐induced syngeneic graft‐vs‐host disease. Transplantation. 1989; 48: 895–900
   PubMed Web of Science ®Google Scholar
• Marcos M A R, De La Hera A, Gaspar M L, Marquez C, Bellas C, Mamposo F, et al. Modification of emerging repertoires by immunsuppression in immunodeficient mice results in autoimmunity. Immunol Rev. 1986; 94: 51–74
   PubMedGoogle Scholar
• Gleichmann E, Van Elven E H, Vander Veen S P W. A systemic lupus erythematosus (SLE)‐like disease in mice induced by abnormal T‐B cell cooperation. Eur J Immunol. 1982; 12: 152–162
   PubMed Web of Science ®Google Scholar
• Jenkins M K, Schwartz R H, Pardoll D M. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–1658
   PubMed Web of Science ®Google Scholar
• Gao E K, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988; 336: 176–179
   PubMed Web of Science ®Google Scholar
• Godden U, Herbert, Stewart R D, Roser B. A novel cell type carrying both Th and Tc/s markers in the blood cyclosporine treated allografted rats. Transplantation. 1985; 39: 624–630
   PubMedGoogle Scholar
• Hess A D, Vogelsang G B, Heyd J, Bèschorner W E. Cyclosporine‐induced syngeneic graft‐vs‐host disease: assessment of T cell differentiation. Transplant Proc. 1987; 19: 2603–2686
   Google Scholar
• Shi Y, Sahai B M, Green D R. Cyclosporin A inhibits activation‐induced cell death in T‐cell hybridomas and thymocytes. Nature 1989; 339: 625–626
   PubMed Web of Science ®Google Scholar
• Nakashima M, Mori K, Maeda K, Kishi H, Hirata M, Kawabushi M, Watanabe T. Selective elimination of double‐positive immature thymocytes by a thymic epithelial cell line. Eur J Immunol. 1990; 20: 47–53
   PubMedGoogle Scholar
• Rothenberg E V. Death and transfiguration of cortical thymocytes. Immunol Today. 1990; 11: 116–119
   PubMedGoogle Scholar
• Quackenbush R C, Shields A F. Local re‐utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine. Cell Tissue Kind. 1988; 21: 381–387
   PubMedGoogle Scholar
• Jenkins M K, Ashwell J D, Schwartz R H. Allogeneic non‐T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen‐presenting cells. J. Immunol. 1988; 140: 3324–3330
   PubMed Web of Science ®Google Scholar
• Lo D, Burkly L C, Flavell R A, Palmiter R D, Brimster R L. Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J Exp Med. 1989; 170: 87–104
   PubMed Web of Science ®Google Scholar
• Schwartz R H. Acquisition of immunologic tolerance. Cell. 1989; 57: 1073–1081
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N. Organ‐specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J Immunol. 1989; 142: 471–480
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N. Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A‐treated mice causes organ‐specific autoimmune disease in athymic nude mice. J Exp Med. 1988; 167: 1479–1485
   PubMed Web of Science ®Google Scholar
• Smith H, Chen I M, Kubo R, Teng K S K. Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus. Science 1989; 245: 749–752
   PubMed Web of Science ®Google Scholar
• Fischer A C, Laulis M K, Horwitz W E, Beschorner W E, Hess A. Host resistance to cyclosporine induced syngeneic graft‐vs‐host‐disease. J Immunol. 1989; 143: 827–832
   PubMed Web of Science ®Google Scholar
• Fischer A C, Hess A D. Age‐related factors in cyclosporine‐induced syngeneic graft‐vs‐host disease: Regulatory role of marrow‐derived T lymphocytes. J Exp Med. 1990; 172: 085–094
   PubMed Web of Science ®Google Scholar
• Lider O, Reshef T, Beraud E, Ben‐Nun A, Cohen I R. Antiidiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988; 239: 181–183
   PubMed Web of Science ®Google Scholar
• Boitard C, Yasunami R, Dardenne M, Bach J F. T cell‐mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med. 1989; 169: 1669–1680
   PubMed Web of Science ®Google Scholar
• Gorczynski R M, Holmes W. Cyclosporine alters the induction of allospecific tolerance in vivo. Immunol. Lett. 1987; 15: 193–197
   PubMedGoogle Scholar
• Prud'homme G J, Bocarro D C. Natural suppressor‐like cells in local graft‐vs‐host disease. Cellular Immunol. 1989; 118: 516–525
   PubMedGoogle Scholar